

# Gary B Kaplan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11686614/publications.pdf>

Version: 2024-02-01

42  
papers

1,935  
citations

236925

25  
h-index

276875

41  
g-index

42  
all docs

42  
docs citations

42  
times ranked

2615  
citing authors

#	ARTICLE	IF	CITATIONS
1	Translational approaches to influence sleep and arousal. <i>Brain Research Bulletin</i> , 2022, 185, 140-161.	3.0	8
2	Sleep-wake and arousal dysfunctions in post-traumatic stress disorder: Role of orexin systems. <i>Brain Research Bulletin</i> , 2022, 186, 106-122.	3.0	17
3	Opioid-induced structural and functional plasticity of medium-spiny neurons in the nucleus accumbens. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 120, 417-430.	6.1	28
4	Suppression and acceptance in unipolar depression: Short-term and long-term effects on emotional responding. <i>British Journal of Clinical Psychology</i> , 2021, , .	3.5	1
5	Pathophysiological Bases of Comorbidity: Traumatic Brain Injury and Post-Traumatic Stress Disorder. <i>Journal of Neurotrauma</i> , 2018, 35, 210-225.	3.4	91
6	Dopamine D1 receptor agonist treatment attenuates extinction of morphine conditioned place preference while increasing dendritic complexity in the nucleus accumbens core. <i>Behavioural Brain Research</i> , 2017, 322, 18-28.	2.2	14
7	Acquisition of morphine conditioned place preference increases the dendritic complexity of nucleus accumbens core neurons. <i>Addiction Biology</i> , 2016, 21, 1086-1096.	2.6	34
8	Associations Among Smoking, Anhedonia, and Reward Learning in Depression. <i>Behavior Therapy</i> , 2014, 45, 651-663.	2.4	70
9	Extinction of opiate reward reduces dendritic arborization and c-Fos expression in the nucleus accumbens core. <i>Behavioural Brain Research</i> , 2014, 263, 51-59.	2.2	20
10	Repeated valproate treatment facilitates fear extinction under specific stimulus conditions. <i>Neuroscience Letters</i> , 2013, 552, 108-113.	2.1	24
11	Dendritic structural plasticity in the basolateral amygdala after fear conditioning and its extinction in mice. <i>Behavioural Brain Research</i> , 2013, 248, 80-84.	2.2	44
12	Separate and Combined Effects of Very Low Nicotine Cigarettes and Nicotine Replacement in Smokers with Schizophrenia and Controls. <i>Nicotine and Tobacco Research</i> , 2013, 15, 121-129.	2.6	54
13	The relationship between reward-based learning and nicotine dependence in smokers with schizophrenia. <i>Psychiatry Research</i> , 2012, 196, 9-14.	3.3	35
14	Opiate Sensitization Induces FosB/Δ FosB Expression in Prefrontal Cortical, Striatal and Amygdala Brain Regions. <i>PLoS ONE</i> , 2011, 6, e23574.	2.5	35
15	Effects of benzodiazepine administration on A1 adenosine receptor binding in-vivo and ex-vivo. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 44, 700-703.	2.4	11
16	Treatment of addiction and anxiety using extinction approaches: Neural mechanisms and their treatment implications. <i>Pharmacology Biochemistry and Behavior</i> , 2011, 97, 619-625.	2.9	82
17	The use of cognitive enhancers in animal models of fear extinction. <i>Pharmacology Biochemistry and Behavior</i> , 2011, 99, 217-228.	2.9	94
18	Effects of contingency management and bupropion on cigarette smoking in smokers with schizophrenia. <i>Psychopharmacology</i> , 2011, 217, 279-287.	3.1	60

#	ARTICLE	IF	CITATIONS
19	Brain-derived neurotrophic factor in traumatic brain injury, post-traumatic stress disorder, and their comorbid conditions: role in pathogenesis and treatment. <i>Behavioural Pharmacology</i> , 2010, 21, 427-437.	1.7	139
20	Intra-VTA adenosine A1 receptor activation blocks morphine stimulation of motor behavior and cortical and limbic Fos immunoreactivity. <i>European Journal of Pharmacology</i> , 2009, 602, 268-276.	3.5	6
21	Effects of smoking abstinence, smoking cues and nicotine replacement in smokers with schizophrenia and controls. <i>Nicotine and Tobacco Research</i> , 2008, 10, 1047-1056.	2.6	36
22	High-dose transdermal nicotine and naltrexone: Effects on nicotine withdrawal, urges, smoking, and effects of smoking.. <i>Experimental and Clinical Psychopharmacology</i> , 2007, 15, 81-92.	1.8	46
23	Subjective and physiological responses to smoking cues in smokers with schizophrenia. <i>Nicotine and Tobacco Research</i> , 2005, 7, 421-429.	2.6	29
24	Cigarette smoking topography in smokers with schizophrenia and matched non-psychiatric controls. <i>Drug and Alcohol Dependence</i> , 2005, 80, 259-265.	3.2	124
25	GABA <sub>B</sub> Receptor Activation in the Ventral Tegmental Area Inhibits the Acquisition and Expression of Opiate-Induced Motor Sensitization. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 308, 667-678.	2.5	79
26	Antipsychotics regulate cyclic AMP-dependent protein kinase and phosphorylated cyclic AMP response element-binding protein in striatal and cortical brain regions in mice. <i>Neuroscience Letters</i> , 2004, 357, 53-57.	2.1	26
27	Baclofen as Adjunctive Treatment for a Patient With Cocaine Dependence and Schizoaffective Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 574-575.	1.4	11
28	Baclofen inhibits opiate-induced conditioned place preference and associated induction of Fos in cortical and limbic regions. <i>Brain Research</i> , 2003, 987, 122-125.	2.2	51
29	Opiate-induced motor stimulation is regulated by $\hat{\gamma}^3$ -aminobutyric acid type B receptors found in the ventral tegmental area in mice. <i>Neuroscience Letters</i> , 2002, 317, 119-122.	2.1	29
30	Differences in Pharmacodynamics but Not Pharmacokinetics Between Subjects With Panic Disorder and Healthy Subjects After Treatment With a Single Dose of Alprazolam. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 338-346.	1.4	15
31	Role of Adenosine A1 and A2A Receptors in the Alcohol Withdrawal Syndrome. <i>Alcohol</i> , 1999, 19, 157-162.	1.7	50
32	Adenosine receptor antagonists inhibit the development of morphine sensitization in the C57BL/6 mouse. <i>Neuroscience Letters</i> , 1999, 264, 89-92.	2.1	24
33	Differential effects of treatment with typical and atypical antipsychotic drugs on adenylyl cyclase and G proteins. <i>Neuroscience Letters</i> , 1999, 273, 147-150.	2.1	17
34	Regulation of G protein-mediated adenylyl cyclase in striatum and cortex of opiate-dependent and opiate withdrawing mice. <i>Brain Research</i> , 1998, 788, 104-110.	2.2	22
35	Regulation of G proteins and adenylyl cyclase in brain regions of caffeine-tolerant and -dependent mice. <i>Brain Research</i> , 1998, 804, 52-62.	2.2	7
36	Adenosine kinase inhibitors attenuate opiate withdrawal via adenosine receptor activation. <i>European Journal of Pharmacology</i> , 1998, 362, 1-8.	3.5	44

#	ARTICLE	IF	CITATIONS
37	Singleâ€•Dose Pharmacokinetics and Pharmacodynamics of Alprazolam in Elderly and Young Subjects. Journal of Clinical Pharmacology, 1998, 38, 14-21.	2.0	27
38	Doseâ€•Dependent Pharmacokinetics and Psychomotor Effects of Caffeine in Humans. Journal of Clinical Pharmacology, 1997, 37, 693-703.	2.0	309
39	Up-regulation of adenosine transporter-binding sites in striatum and hypothalamus of opiate tolerant mice. Brain Research, 1997, 763, 215-220.	2.2	35
40	Alterations of adenosine A1 receptors in morphine dependence. Brain Research, 1994, 657, 347-350.	2.2	46
41	Separate and combined effects of caffeine and alprazolam on motor activity and benzodiazepine receptor binding in vivo. Psychopharmacology, 1990, 101, 539-544.	3.1	13
42	Caffeineâ€•induced behavioural stimulation is doseâ€•and concentrationâ€•dependent. British Journal of Pharmacology, 1990, 100, 435-440.	5.4	28